Modulation of cell cycle progression in human tumors: A pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850)

Clinical Cancer Research

Volumn 12, Issue 23, 2006, Pages 7079-7085

  Perez, Raymond P ^a,b   Lewis, Lionel D ^a   Beelen, Andrew P ^a   Olszanski, Anthony J ^a   Johnston, Nicholas ^a   Rhodes, C Harker ^a   Beaulieu, Bernard ^a   Ernstoff, Marc S ^a   Eastman, Alan ^a  

^a NORRIS COTTON CANCER CENTER   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; CISPLATIN;

ADULT; AGED; ARTICLE; ATOMIC ABSORPTION; CANCER; CELL CYCLE PROGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HALF LIFE; FEMALE; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBARACHNOID HEMORRHAGE; TUMOR BIOPSY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, FINE-NEEDLE; CELL CYCLE; CISPLATIN; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MAXIMUM TOLERATED DOSE; NEOPLASMS; PREDICTIVE VALUE OF TESTS; STAUROSPORINE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 33746388284     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0197     Document Type: Article

References (29)

1. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821-8.
2. Rhind N, Russell P. Checkpoints: it takes more than time to heal some wounds. Curr Biol 2000;10: R908-11.
3. Tobey RA. Different drugs arrest cells at a number of distinct stages in G2. Nature 1975;254:245-7.
4. Sanchez Y, Wong C, Thoma RS, et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 1997;277:1497-501.
5. Luo Y, Rocknow-Magnone SK, Kroeger PE, et al. Blocking Chk1 expression induces apoptosis and abrogates the G2 checkpoint mechanism. Neoplasia 2001;3:411-9.
6. 2-checkpoint inhibitor. Clin Cancer Res 1996;2:791-7.
7. Lee SI, Brown MK, Eastman A. Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines. Biochem Pharmacol 1999;58:1713-21.
8. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000;60: 2108-12.
9. Zhao B, Bower MJ, McDevitt PJ, et al. Structural basis for Chk1 inhibition by UCN-01. J Biol Chem 2002; 277:46609-15.
10. Wang O, Fan S, Eastman A, Worland P, Sausville E, O'Connor P. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996;88:956-65.
11. Shao R-G, Cao C-X, Shimizu T, O'Connor PM, Kohn KW, Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997;57:4029-35.
12. 2 checkpoint abrogation. Int J Cancer 2000;85:703-9.
13. Levesque AA, Kohn EA, Bresnick E, Eastman A. Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints. Oncogene 2005;24:3786-96.
14. Kohn EA, Ruth ND, Brown MK, Livingstone M, Eastman A. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of UCN-01 and the kinetics of Cdc25C activation. J Biol Chem 2002;277:26553-64.
15. Sausville EA, Arbuck SG, Messmann R, et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001;19:2319-33.
16. Dees EC, Baker S, O'Reilly S, et al. A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. Clin Cancer Res 2005;11:664-71.
17. Tamura T, Sasaki Y, Minami H, et al. Phase I study of UCN-01 by 3-hour infusion. Proc Am Soc Clin Oncol 1999;18:611a.
18. Fuse E, Tanii H, Kurata N, et al. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human α1-acid glycoprotein. Cancer Res 1998;58: 3248-53.
19. Sparreboom A, Chen H, Acharya MR, et al. Effects of α-1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine. Clin Cancer Res 2004;10:6840-6.
20. Sausville E, Lush R, Headlee D, et al. Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. Cancer Chemother Pharmacol 1998;42 suppl:s54-9.
21. Simon R, Freidlin B, Rubenstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-47.
22. Bauer KS, Lush RM, Rudek MA, Shih C, Sausville E, Figg WD. A high-performance liquid chromatography method using ultraviolet and fluorescence detection for quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva. Biomed Chromatogr 2000;14:338-43.
23. Kortmansky J, Shah MA, Kaubisch A, et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors. J Clin Oncol 2005;23:1875-84.
24. Lara PN, Mack PC, Synold T, et al. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California Cancer Consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res 2005;11:4444-50.
25. Israili ZH, Dayton PG. Human α-1-glycoprotein and its interactions with drugs. Drug Metab Rev 2001;33: 161-235.
26. Fournier T, Medjoubi-N, N, Porquet D. α-1-Acid glycoprotein. Biochim Biophys Acta 2000;1482:157-71.
27. Gonzalez MA, Tachibana KE, Chin SF, et al. Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. J Pathol 2004;204: 121-30.
28. Eastman A, Kohn EA, Brown MK, et al. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity. Similarities and differences to the cell cycle checkpoint abrogator UCN-01. Mol Cancer Ther 2002;1: 1067-78.
29. Kohn EA, Yoo CJ, Eastman A. The protein kinase C inhibitor Go6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res 2003;63:31-5.